Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Q4 Revenues Leap 163 Percent as Profits Soar

NEW YORK (GenomeWeb News) — Illumina today said fourth-quarter revenues jumped 163 percent as R&D spending rose 17 percent and profit soared.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $60.4 million from $23 million year over year.
 
R&D spending increased to $8.8 million from $7.5 million year over year.
 
The company said profit increased to $17.1 million from $326,000 in the year-ago period.
 
Illumina said it had around $130.7 million in cash, cash equivalents, and short-term investments as of Dec. 31.
 
The company said it expects 2007 revenue to be between $295 million and $315 million. First-quarter revenues are expected to be between $64 million and $68 million.
 
In the fourth quarter, Illumina completed the acquisition of Solexa for $600 million, and added two Solexa board members to its board.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.